A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The ...

HOUSTON, Texas (KTRK) -- The Food and Drug Administration is currently reviewing a first-of-its-kind, twice-yearly injectable medication that experts say could revolutionize HIV prevention. The drug, ...

Young women, mothers holding babies and some men lined up in a dusty field on the outskirts of Zimbabwe’s capital, Harare.

Researchers discovered antibody 007, which binds to the V3 glycan site on HIV-1, required for viral entry into immune cells.

Over the past three decades, there have been amazing advances in treating and preventing HIV. Subscribe to our newsletter for the latest sci-tech news updates. It's now a manageable infection. A ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation.